Consort Medical PLC (CSRT.LN), a U.K. maker of medical devices for inhaled drug delivery and self-injection, Monday said that the U.S. Food and Drug Administration has approved the first product to use its Bespak division's Integrated Dose Counter, or IDC.

The IDC is being used with Teva Pharmaceutical Industries Ltd.'s (TEVA) QNASL Nasal Aerosol for the treatment of nasal symptoms associated with seasonal allergic rhinitis and perennial allergic rhinitis in adults and adolescents.

Consort said its Bespak business, which develops devices to deliver drugs to sufferers of asthma and chronic obstructive pulmonary disease, has been developing its IDC for a number of years.

The device provides patients with an easy-to-read indication of how many doses are left inside the canister.

Consort Medical's shares closed Friday at 656.0 pence.

-By Jana Weigand, Dow Jones Newswires; 44-20-7842-9314; jana.weigand@dowjones.com